Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Journal: The British journal of ophthalmology
Published: May 12, 2021
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: November 19, 2020
Showing 1-2 of 2
Last Updated: 09/26/2026